Contribute Try STAT+ Today

Massachusetts General Hospital will soon start the first clinical trial that simultaneously tests multiple potential ALS medicines in the hopes of getting results faster at lower costs.

The Boston teaching hospital plans to launch the first “platform trial” in early 2020 at the Sean M. Healey & AMG Center for ALS, which was founded last year with $40 million in donations. The trial will be run by MGH, start off with five medicines, and take place at 54 clinical sites in the country.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.